Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Impact of aging and HIV infection on serologic response to seasonal influenza vaccination

Pallikkuth, Suresha; De Armas, Lesley, R.a; Pahwa, Rajendraa; Rinaldi, Stefanoa; George, Varghese, K.a; Sanchez, Celeste, M.a; Pan, Lia; Dickinson, Gordonb,d; Rodriguez, Allanb; Fischl, Margaretc; Alcaide, Mariab; Pahwa, Savitaa

Erratum

There are two errors in this article [1] the first sentence of the Methods section of the Abstract. The number of HIV+ individuals should be 154 and not 151, and the number of HIV- individuals should be 161 and not 164.

AIDS. 33(4):771, March 15, 2019.

doi: 10.1097/QAD.0000000000001774
BASIC SCIENCE
Buy
SDC
Erratum

Objective: To determine influence of age and HIV infection on influenza vaccine responses.

Design: Evaluate serologic response to seasonal trivalent influenza vaccine (TIV) as the immunologic outcome in HIV-infected (HIV+) and age-matched HIV negative (HIV) adults.

Methods: During 2013–2016, 151 virologically controlled HIV+ individuals on antiretroviral therapy and 164 HIV volunteers grouped by age as young (<40 years), middle aged (40–59 years) and old (≥60 years) were administered TIV and investigated for serum antibody response to vaccine antigens.

Results: At prevaccination (T0) titers were in seroprotective range in more than 90% of participants. Antibody titers increased in all participants postvaccination but frequency of classified vaccine responders to individual or all three vaccine antigens at 3–4 weeks was higher in HIV than HIV+ adults with the greatest differences manifesting in the young age group. Of the three vaccine strains in TIV, antibody responses at T2 were weakest against H3N2 with those to H1N1 and B antigens dominating. Among the age groups, the titers for H1N1 and B were lowest in old age, with evidence of an age-associated interaction in HIV+ persons with antibody to B antigen.

Conclusion: Greater frequencies of vaccine nonresponders are seen in HIV+ young compared with HIV adults and the observed age-associated interaction for B antigen in HIV+ persons are supportive of the concept of premature immune senescence in controlled HIV infection. High-potency influenza vaccination recommended for healthy aging could be considered for HIV+ adults of all ages.

aDepartment of Microbiology and Immunology, Miami Center for AIDS Research

bDivision of Infectious Disease

cAIDS Clinical Research Unit, Department of Medicine, University of Miami Miller School of Medicine

dMiami Veteran Affairs Medical Center, Miami, Florida, USA.

Correspondence to Savita Pahwa, Department of Microbiology and Immunology, Miami Center for AIDS Research, University of Miami Miller School of Medicine, 1580 NW 10th Ave., Miami, FL 33136, USA. E-mail: Spahwa@med.miami.edu

Received 16 October, 2017

Revised 27 December, 2017

Accepted 8 January, 2018

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

Copyright © 2018 Wolters Kluwer Health, Inc.